REFERENCES
1. Iung B, Delgado V, Rosenhek R, et al. ; EORP VHD II Investigators. Contemporary Presentation and Management of Valvular Heart disease: The EUR observational research programme valvular heart disease II survey. Circulation. 2019;140:1156-69.
2. Unger P, Tribouilloy C. Aortic stenosis with other concomitant valvular disease: aortic regurgitation, mitral regurgitation, mitral stenosis, or tricuspid regurgitation. Cardiol Clin. 2020;38:33-46.
3. Badhwar V, Chikwe J, Gillinov AM, et al. Risk of surgical mitral valve repair for primary mitral regurgitation. J Am Coll Cardiol. 2023;81:636-48.
4. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: executive summary: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2021;143:e35-71.
5. Deja MA, Malinowski M, Widenka K, et al. Repair or replacement for secondary mitral regurgitation: results from polish national registry. Ann Thorac Surg. 2022;113:146-56.
6. Vahanian A, Beyersdorf F, Praz F, et al. ; ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561-632.
7. Gavazzoni M, Taramasso M, Zuber M, et al. Conceiving MitraClip as a tool: percutaneous edge-to-edge repair in complex mitral valve anatomies. Eur Heart J Cardiovasc Imaging. 2020;21:1059-67.
8. Elbadawi A, Dang AT, Hamed M, et al. Transcatheter edge-to-edge repair for mitral regurgitation using PASCAL or MitraClip. Catheter Cardiovasc Interv. 2023;102:521-7.
9. Wang J, Liu X, Pu Z, et al. Safety and efficacy of the DragonFly system for transcatheter valve repair of degenerative mitral regurgitation: one-year results of the DRAGONFLY-DMR trial. EuroIntervention. 2024;20:e239-49.
10. Feldman T, Foster E, Glower DD, et al. ; EVEREST II Investigators. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364:1395-406.
11. von Bardeleben RS, Mahoney P, Morse MA, et al. 1-year outcomes with fourth-generation mitral valve transcatheter edge-to-edge repair from the EXPAND G4 Study. JACC Cardiovasc Interv. 2023;16:2600-10.
12. Zahr F, Smith RL, Gillam LD, et al. 1-year outcomes from the CLASP IID randomized trial for degenerative mitral regurgitation. 2023;16:2803-16.
13. Stone GW, Lindenfeld J, Abraham WT, et al. ; COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379:2307-18.
14. Anker SD, Friede T, von Bardeleben RS, et al. ; RESHAPE-HF2 Investigators. Transcatheter valve repair in heart failure with moderate to severe mitral regurgitation. N Engl J Med. 2024;391:1799-809.
15. Stocker TJ, Stolz L, Karam N, et al. ; EuroSMR Investigators. Long-term outcomes after edge-to-edge repair of secondary mitral regurgitation: 5-year results from the EuroSMR registry. JACC Cardiovasc Interv. 2024;17:2543-54.
16. Kar S, von Bardeleben RS, Rottbauer W, et al. Contemporary outcomes following transcatheter edge-to-edge repair: 1-year results from the EXPAND study. JACC Cardiovasc Interv. 2023;16:589-602.
17. Webb JG, Hensey M, Szerlip M, et al. 1-year outcomes for transcatheter repair in patients with mitral regurgitation from the CLASP study. JACC Cardiovasc Interv. 2020;13:2344-57.
18. Spargias K, Lim DS, Makkar R, et al. Three-year outcomes for transcatheter repair in patients with mitral regurgitation from the CLASP study. Catheter Cardiovasc Interv. 2023;102:145-54.
19. Taramasso M, Maisano F, Latib A, et al. Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation. EuroIntervention. 2014;10:746-52.
20. Higuchi S, Orban M, Stolz L, et al. Impact of residual mitral regurgitation on survival after transcatheter edge-to-edge repair for secondary mitral regurgitation. JACC Cardiovasc Interv. 2021;14:1243-53.
21. Boekstegers P, Hausleiter J, Schmitz T, et al. ; MITRA-PRO Investigators. Intraprocedural residual mitral regurgitation and survival after transcatheter edge-to-edge repair: prospective German multicenter registry (MITRA-PRO). JACC Cardiovasc Interv. 2023;16:574-85.
22. Singh GD, Price MJ, Shuvy M, et al. Combined impact of residual mitral regurgitation and gradient after mitral valve transcatheter edge-to-edge repair. JACC Cardiovasc Interv. 2024;17:2530-40.
23. Hausleiter J, Stocker TJ, Adamo M, Karam N, Swaans MJ, Praz F. Mitral valve transcatheter edge-to-edge repair. EuroIntervention. 2023;18:957-76.
24. Sugiura A, Kavsur R, Spieker M, et al. Recurrent mitral regurgitation after MitraClip: predictive factors, morphology, and clinical implication. Circ Cardiovasc Interv. 2022;15:e010895.
25. Sorajja P, Vemulapalli S, Feldman T, et al. Outcomes with transcatheter mitral valve repair in the United States: An STS/ACC TVT registry report. J Am Coll Cardiol. 2017;70:2315-27.
26. Adamo M, Pagnesi M, Popolo Rubbio A, et al. Predictors of optimal procedural result after transcatheter edge-to-edge mitral valve repair in secondary mitral regurgitation. Catheter Cardiovasc Interv. 2022;99:1626-35.
27. Orban M, Rottbauer W, Williams M, et al. Transcatheter edge-to-edge repair for secondary mitral regurgitation with third-generation devices in heart failure patients - results from the Global EXPAND Post-Market study. Eur J Heart Fail. 2023;25:411-21.
28. Kubo S, Yamamoto M, Saji M, et al. ; OCEAN‐Mitral Investigators. One-year outcomes and their relationship to residual mitral regurgitation after transcatheter edge-to-edge repair with MitraClip device: insights from the OCEAN-mitral registry. J Am Heart Assoc. 2023;12:e030747.
29. Chhatriwalla AK, Vemulapalli S, Szerlip M, et al. Operator experience and outcomes of transcatheter mitral valve repair in the United States. J Am Coll Cardiol. 2019;74:2955-65.
30. Taramasso M, Gavazzoni M, Nickenig G, Maisano F. Transcatheter mitral repair and replacement: which procedure for which patient? EuroIntervention. 2019;15:867-74.
31. Muller DWM, Farivar RS, Jansz P, et al. ; Tendyne global feasibility trial investigators. Transcatheter mitral valve replacement for patients with symptomatic mitral regurgitation: a global feasibility trial. J Am Coll Cardiol. 2017;69:381-91.
32. Fukui M, Sorajja P, Gössl M, et al. Left ventricular remodeling after transcatheter mitral valve replacement with Tendyne: new insights from computed tomography. JACC Cardiovasc Interv. 2020;13:2038-48.
33. Muller DWM, Sorajja P, Duncan A, et al. 2-year outcomes of transcatheter mitral valve replacement in patients with severe symptomatic mitral regurgitation. J Am Coll Cardiol. 2021;78:1847-59.
34. Hell MM, Wild MG, Baldus S, et al. ; TENDER Investigators. Transapical mitral valve replacement: 1-year results of the real-world Tendyne European experience registry. JACC Cardiovasc Interv. 2024;17:648-61.
35. Ben Ali W, Ludwig S, Duncan A, et al. ; CHOICE-MI Investigators. Characteristics and outcomes of patients screened for transcatheter mitral valve implantation: 1-year results from the CHOICE-MI registry. Eur J Heart Fail. 2022;24:887-98.
36. Al-Tawil M, Butt S, Reap S, et al. Transseptal vs transapical transcatheter mitral valve-in-valve and valve-in-ring implantation: a systematic review and meta-analysis. Curr Probl Cardiol. 2023;48:101684.
37. Anselmi A, Leurent G, Donal E. Transcatheter mitral valve replacement: technology update. advances in cardiovascular technology. Elsevier; 2022. pp. 319-34.
38. Tartaglia F, Antonelli G, Gitto M, et al. TMVR for the treatment of mitral regurgitation: a state-of-the-art review. Circ Cardiovasc Interv. 2025;18:e015298.
39. Zahr F, Song HK, Chadderdon S, et al. 1-year outcomes following transfemoral transseptal transcatheter mitral valve replacement: intrepid TMVR early feasibility study results. JACC Cardiovasc Interv. 2023;16:2868-79.
40. Schneider LM, Worthley S, Nickenig G, et al. 1-year outcomes following transfemoral transseptal transcatheter mitral valve replacement: The HighLife TSMVR feasibility study. JACC Cardiovasc Interv. 2023;16:2854-65.
41. Maisano F. Cardiovalve device attributes, implant procedure and early results. Presented at EuroPCR 2019; May 22, 2019; Paris, France. https://www.tctmd.com/slide/cardiovalve-device-attributes-implant-procedure-and-early-results. (accessed 7 January 2026).
42. Kaneko et al. AltaValve Early Feasibility Study Results. Presented at: PCR Tokyo Valves 2025. T. AltaValve System Early Feasibility Study Results. AltaValve Early Feasibility Study Results Presented at: PCR Tokyo Valves 2025. https://www.pcronline.com/Cases-resources-images/Resources/Course-videos-slides/2025/PCR-Tokyo-Valves/Late-Breaking-Trial-session. (accessed 7 January 2026).
43. Granada JF. Cephea TMVR Program Technology and Clinical Update. Presented at: New York Valves; June 26, 2025; New York, USA. Available from: https://d14d5nk8lue86f.cloudfront.net/public/2025-06/5dba363c-2b20-470c-b9e0-79974d7a5983.pdf. (accessed 30 December 2025).
44. Makkar R, O'neill W, Whisenant B, et al. TCT-8 updated 30-day outcomes for the U.S. early feasibility study of the SAPIEN M3 transcatheter mitral valve replacement system. J Am Coll Cardiol. 2019;74:B8.
45. Meerkin D, Guetta V, Shaburishvili T, et al. Early experience with the innovalve transcatheter mitral valve replacement system. JACC Cardiovasc Interv. 2024;17:712-4.
46. Meredith I, Bapat V, Morriss J, McLean M, Prendergast B. Intrepid transcatheter mitral valve replacement system: technical and product description. EuroIntervention. 2016;12:Y78-80.
47. Zahr F, Song HK, Chadderdon SM, et al. 30-day outcomes following transfemoral transseptal transcatheter mitral valve replacement: intrepid TMVR early feasibility study results. JACC Cardiovasc Interv. 2022;15:80-9.
48. Lange R, Piazza N. The HighLife transcatheter mitral valve implantation system. EuroIntervention. 2015;11 Suppl W:W82-3.
49. Maisano F, Benetis R, Rumbinaite E, et al. 2-year follow-up after transseptal transcatheter mitral valve replacement with the cardiovalve. JACC Cardiovasc Interv. 2020;13:e163-4.
50. Sherif M, Sündermann SH, Maisano F, et al. Cardiovalve in mitral valve position-additional solution for valve replacement. Front Cardiovasc Med. 2022;9:960849.
51. Généreux P, Wróbel K, Rinaldi MJ, et al. AltaValve atrial fixation system for the treatment of severe mitral regurgitation and mitral annular calcification. Struct Heart. 2024;8:100294.
52. Généreux P, Wróbel K, Ninios V, et al. 6-month outcomes of a supra-annular transcatheter mitral valve replacement: an early feasibility study. JACC Cardiovasc Interv. 2025;18:2584-92.
53. Coisne A, Rodés-Cabau J, Ludwig S, et al. Impact of a dedicated transseptal transcatheter mitral valve replacement system on cardiac remodeling and hemodynamics. JACC Cardiovasc Interv. 2023;16:1310-2.
54. Modine T, Vahl TP, Khalique OK, et al. First-in-human implant of the Cephea transseptal mitral valve replacement system. Circ Cardiovasc Interv. 2019;12:e008003.
55. Alperi A, Dagenais F, Del Val D, et al. Early experience with a novel transfemoral mitral valve implantation system in complex degenerative mitral regurgitation. JACC Cardiovasc Interv. 2020;13:2427-37.
56. Penteris M, Lampropoulos K. The SAPIEN M3 system for transcatheter mitral valve replacement: a new era begins. Cardiovasc Revasc Med. 2025;79:120-5.
57. Webb JG, Murdoch DJ, Boone RH, et al. Percutaneous transcatheter mitral valve replacement: first-in-human experience with a new transseptal system. J Am Coll Cardiol. 2019;73:1239-46.
58. Husain A, Meier D, Dundas J, et al. Transcatheter mitral valve replacement: 5 years later. JACC Cardiovasc Interv. 2023;16:2920-2.
59. Niikura H, Gössl M, Kshettry V, et al. Causes and clinical outcomes of patients who are ineligible for transcatheter mitral valve replacement. JACC Cardiovasc Interv. 2019;12:196-204.
